Compare DIN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIN | CLLS |
|---|---|---|
| Founded | 1958 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.1M | 438.4M |
| IPO Year | 1991 | 2007 |
| Metric | DIN | CLLS |
|---|---|---|
| Price | $35.24 | $3.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $31.67 | $8.50 |
| AVG Volume (30 Days) | ★ 404.1K | 41.5K |
| Earning Date | 03-04-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $866,500,000.00 | $82,551,000.00 |
| Revenue This Year | $10.69 | $32.58 |
| Revenue Next Year | $2.20 | $20.68 |
| P/E Ratio | $15.59 | ★ N/A |
| Revenue Growth | 6.47 | ★ 129.04 |
| 52 Week Low | $18.63 | $1.10 |
| 52 Week High | $39.68 | $5.48 |
| Indicator | DIN | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 33.51 |
| Support Level | $33.71 | $4.04 |
| Resistance Level | $36.06 | $3.95 |
| Average True Range (ATR) | 1.36 | 0.21 |
| MACD | -0.28 | -0.07 |
| Stochastic Oscillator | 29.95 | 8.05 |
Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.